Wide Ranks

CTSO

Cytosorbents Corporation

0.9102

Top Statistics
Market Cap 49 M Forward PE -6.50 Revenue Growth 6.60 %
Current Ratio 1.97 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -49.47 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -3.59 Enterprise / Revenue 1.88 Price To Sales Trailing12 Months 1.32
Profitability
Profit Margins -49.47 % Operating Margins -46.13 %
Balance Sheet
Total Cash 5 M Total Cash Per Share 0.1040 Total Debt 26 M
Total Debt To Equity 206.22 Current Ratio 1.97 Book Value Per Share 0.2390
All Measures
Short Ratio 927.00 % Message Board Id finmb_628213 Fax 732 329 8650
Shares Short Prior Month 1 M Return On Equity -1.18 City Princeton
Uuid a1428858-7dce-3401-be66-dca6a5eea2d9 Previous Close 0.8993 First Trade Date Epoch Utc 1 B
Book Value 0.2390 Beta 0.5640 Total Debt 26 M
Volume 147707 Price To Book 3.81 Last Split Date 1 B
Fifty Two Week Low 0.7000 Total Cash Per Share 0.1040 Total Revenue 37 M
Shares Short Previous Month Date 1 B Target Median Price 4.00 Max Age 86400
Recommendation Mean 2.00 Sand P52 Week Change 0.3133 Operating Margins -46.13 %
Target Mean Price 5.00 Net Income To Common -18670004 Short Percent Of Float 0.0244
Implied Shares Outstanding 54 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 113940 Average Volume10days 113940 Total Cash 5 M
Next Fiscal Year End 1 B Revenue Per Share 0.7200 Held Percent Insiders 0.0382
Ebitda Margins -52.29 % Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 0.8993 Target Low Price 1.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 1.09 Open 0.9200
Free Cashflow -11946897 State NJ Dividend Yield 0.00 %
Return On Assets -0.2793 Time Zone Short Name EST Trailing Eps -0.3600
Day Low 0.9071 Address1 305 College Road East Shares Outstanding 54 M
Price Hint 4 Target High Price 10.00 Website https://www.cytosorbents.com
52 Week Change -0.2417 Average Volume 117531 Forward Eps -0.1400
Recommendation Key buy Compensation As Of Epoch Date 1 B Quick Ratio 146.10 %
Last Split Factor 1:25 Regular Market Day High 0.9501 Is_sp_500 False
Profit Margins -49.47 % Debt To Equity 206.22 Fifty Two Week High 2.15
Day High 0.9501 Shares Short 1 M Regular Market Open 0.9200
Industry Key medical-devices Earnings Growth 0.00 % Enterprise To Revenue 1.88
Revenue Growth 6.60 % Shares Percent Shares Out 0.0238 Operating Cashflow -18493052
Currency USD Time Zone Full Name America/New_York Market Cap 49 M
Is_nasdaq_100 False Zip 08540 Quote Type EQUITY
Industry Medical Devices Long Name Cytosorbents Corporation Regular Market Day Low 0.9071
Held Percent Institutions 0.3346 Current Price 0.9102 Enterprise To Ebitda -3.59
Financial Currency USD Current Ratio 1.97 Gross Margins 62.71 %
Industry Disp Medical Devices Number Of Analyst Opinions 3 Country United States
Float Shares 46 M Two Hundred Day Average 0.9873 Enterprise Value 70 M
Price To Sales Trailing12 Months 1.32 Forward PE -6.50 Regular Market Volume 147707
Ebitda -19732864 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally.

Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.

The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy.

In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system.

The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010.

Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.